<DOC>
	<DOCNO>NCT01503892</DOCNO>
	<brief_summary>This study focus use Metanx® sole treatment improve reverse nerve damage type 2 diabetic patient peripheral neuropathy . There two equal study group enrol randomize double blind study . The minimum sample size enrollment 24 ( 12 per group ) , require 90 % power alpha = .05 . The maximum number participant set 100 ( 50 per group ) . Patients pre-diabetic patient diagnose diabetes type II less five year include study . The control group receive placebo pill twice daily versus treatment group receive one Metanx® tablet twice daily . Each group intraepidermal nerve fiber density obtain skin biopsy take begin study treatment begin well final intraepidermal nerve skin biopsy end twelve month re-biopsy . In addition group answer three set questionnaires relate peripheral neuropathy initial , three month , twelve month visitation . If Metanx® able reverse nerve damage improve symptom final nerve biopsy show increase intraepidermal nerve fiber density improvement subjective score versus placebo group .</brief_summary>
	<brief_title>Metanx Effects Nerve Fiber Density Neuropathic Diabetics</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Vitamin B 12</mesh_term>
	<criteria>Type 2 Diabetics Prediabetics Symptoms peripheral neuropathy Pregnancy Under age 18 HIV ( + )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Small Fiber Neuropathy</keyword>
	<keyword>Metanx Effect Small Fiber Neuropathy</keyword>
	<keyword>Metanx Effect Diabetic Peripheral Neuropathy</keyword>
</DOC>